Pharmaxis' (ASX:PXS) chief executive officer, Gary Phillips, provides details on clinical trials and Boehringer Ingelheim agreement with Proactive Investors.
Pharmaxis is a specialist pharmaceutical company with a portfolio of products at various stages of development and approval.
In May 2015, Boehringer Ingelheim acquired the Pharmaxis investigational drug PXS4728A, to develop it for the treatment of the liver-related condition NASH.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.